Euroscreen S.A.
Records under this name other than patents Euroscreen S.A. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,824,866 | Ligand for G-protein coupled receptor GPR72 and uses thereof Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 8,497,075 | Methods of identifying a modulator that inhibits the binding between Epstein-Barr Virus induced receptor 2 and cholesterol derived ligands Formerly held In force · High confidence | In force | High confidence | |
| US 8,871,761 | NK-3 receptor selective antagonist compounds, pharmaceutical composition and methods for use in NK-3 receptors mediated disorders Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 9,926,325 | NK-3 receptor selective antagonist compounds, pharmaceutical composition and methods for use in NK-3 receptors mediated disorders Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 10,065,960 | NK-3 receptor selective antagonist compounds, pharmaceutical composition and methods for use in NK-3 receptors mediated disorders Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 9,695,120 | Substituted pyrrolidines as G-protein coupled receptor 43 agonists Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 9,475,814 | Chiral N-acyl-5,6,7(8-substituted)-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists, pharmaceutical composition, methods for use in NK-3 receptor mediated disorders and chiral synthesis thereof Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 10,065,961 | Chiral N-acyl-5,6,7,(8-substituted)-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists, pharmaceutical composition, methods for use in NK-3 receptor mediated disorders and chiral synthesis thereof Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 9,840,508 | N-acyl-(3-substituted)-(8-methyl)-5,6-dihydro-[1,2,4]triazolo[4,3-a] pyrazines as selective NK-3 receptor antagonists, pharmaceutical composition, methods for use in NK-3 receptor-mediated disorders Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 9,969,738 | N-acyl-(3-substituted)-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists, pharmaceutical composition, methods for use in NK-3 receptor-mediated disorders Formerly held In force · From the USPTO record | In force | From the USPTO record |